93 POSTER Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors (VEGFR), in combination with oxaliplatin and Infusional 5-Fu (mFOLFOX6) in patients with advanced colorectal cancer (CRC): a study of the National Cancer Institute of Canada Clinical Trials Group
E. Chen, D. Jonker, M. Maclean, J. Wells, S. Mathews, J. Robertson, L. SeymourVolume:
4
Year:
2006
Language:
english
DOI:
10.1016/s1359-6349(06)70099-4
File:
PDF, 57 KB
english, 2006